Ackman: Pershing Square Gets Senate Inquiry on Drug Prices
- Activist says company will cooperate fully with requests
- Valeant is one of drugmakers receiving congressional scrutiny
Bill Ackman.
Photographer: Andrew Harrer/BloombergThis article is for subscribers only.
Bill Ackman said his public company, Pershing Square Holdings Ltd., which mirrors the activist’s hedge fund holdings, had received a request from a Senate committee looking into pricing of off-patent drugs.
The request was revealed in the company’s annual report released Thursday.